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Objective. Sclerotherapy (IS) or ambulatory phlebectomy (AP) are required as subsequent interventions in majority
of cases following endovenous laser therapy (EVLT). We assessed whether AP performed concomitantly with EVLT
(EVLTAP), is effective, acceptable, and reduces subsequent requirement for interventions.
Method. 67 patients (70 limbs) with great saphenous varicosities underwent EVLTAP. Pain was assessed on days 1, 4 and
7 using a visual analogue scale (VAS) of 0 to 10. Clinical and ultrasound assessments were done at 1, 6 and 12 weeks (no
ultrasound at 6 weeks). Residual varicosities underwent further AP or IS. Patients’ satisfaction with the cosmetic outcome
and overall treatment was assessed at 12 weeks using a VAS rating.
Results. 49 patients (70%) completed follow-up. Median pain scores were 1.6 (IQR 0.2e4.8), 0.3 (0e1.4) and 0.2 (0e1.1)
on days 1, 4 and 7 respectively. Ultrasound demonstrated 69 (99%) and 47 (96%) occluded long saphenous veins at 1 and
12 weeks respectively. Subsequent IS or AP was performed on 3 (4%) or 1 (1%) limbs respectively. Cosmetic satisfaction
was 9.6 (IQR 8.9e10) and overall satisfaction 9.8 (IQR 9.3e10).
Conclusion. EVLTAP produces excellent results, is feasible and acceptable, and obviates need for subsequent procedures in
the short-term.
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Lower limb varicose veins are common, affecting 40%
of men and 32% of women in the United Kingdom.1
Many patients are asymptomatic, but complaints
may range from subjective symptoms such as aching,
leg heaviness, pruritus, and muscle cramps, to more
objective features of oedema, eczema, lipodermato-
sclerosis and ulceration.2e4 There is a correlation
between symptoms and extent of reflux.5 Patients
may seek treatment because of these symptoms or
because of cosmetic appearance. Although not com-
monly addressed, patients’ concerns, worries or fears
about their varicose veins are important reasons for
seeking treatment.4
By far the vast majority (60e80%) of varicose veins
arise from incompetence of the sapheno-femoral junc-
tion (SFJ) and great saphenous vein (GSV) reflux.5,6
Successful long term surgical treatment of varicose
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and the incompetent segments of veins.7e9 For long
saphenous varicosities, the procedure of choice is
SFJ ligation, GSV stripping to the knee level and mul-
tiple avulsions of varicosities.2,7e10 Surgery usually
requires general anaesthesia and is associated with
significant perioperative morbidity, increased cost of
hospitalisation and delayed return to normal activities
and work.3,8,10,11 Recurrence rates vary from 20% to
80% depending on definition and timing.11e14
In recent years, minimally invasive techniques of
varicose veins treatment have emerged as alternatives
to surgery. Endovenous delivery of laser energy was
first reported in 1999,15 and endovenous laser ablation
of the GSV was achieved 2 years later.8 Excellent
GSV occlusion rates at 5 years follow up have been
reported, with clinical improvement of symptoms.16
Complications following EVLT are infrequent, how-
ever 30%e99% of patients require secondary treatment
of residual varicosities, usually in the form of compres-
sion sclerotherapy post EVLT.11 The need for second-
ary sclerotherapy with its associated potential
complications, may be a relative limitation to the other-
wise high patient acceptability of EVLT.rved.
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bulatory phlebectomy as a single procedure (EVLTAP),
is feasible, effective and acceptable to patients.
Methods
Patients
The study population comprised 67 patients (31 men
and 36 women; median age 49 [IQR 35e58] years)
with varicose veins secondary to isolated SFJ incom-
petence and GSV reflux confirmed by duplex ultra-
sound scan. Patients were C2 (n¼ 45), C4 (n¼ 24)
and C5 (n¼ 1) according to the CEAP classification.
Patients were selected by screening the day-case varicose
veins waiting list, and inviting patients listed for SFJ
ligation, GSV stripping and phlebectomies for duplex scan-
ning. Patients who matched our local suitability criteria
were offered EVLTAP. Patients with small saphenous vari-
cosities, anterolateral thigh branch incompetence, previous
varicose vein surgery and GSV with a diameter of less
than 5 mm at the knee were excluded.
All patients signed an informed consent form
before undergoing EVLTAP. 70 unilateral procedures
were carried out in these patients (3 patients with
bilateral varicose veins underwent staged procedures).
The study was approved by the Hull and East Riding
Local Research Ethics Committee and carried out in
accordance with the Helsinki Declaration.
Technique description
All procedures commenced with laser ablation of the
incompetent GSV. The SFJ was identified by DUS
in the upright position and the course of the GSV
followed down to the knee, with intermittent skin
markings. The patient was positioned in the reverse
trendelenburg position and skin preparation and
draping carried out. The peri-genicular entry point
into the GSV was again identified and 1e2 ml of 1%
plain lignocaine infiltrated into the skin. Percutaneous
entry into the GSV was gained, using a 19-guage nee-
dle under ultrasound guidance. In 2 patients where
percutaneous cannulation of the GSV at the knee
was impossible due to small vein size, open cannula-
tion was achieved via a stab wound. A 0.035-inch di-
ameter J guide wire was inserted through the needle,
which was subsequently removed. A 5 Fg catheter
was introduced over the guide wire and positioned
within the GSV, immediately distal to the SFJ. Its
position was confirmed by ultrasound, and the aspira-
tion of non-pulsatile blood. A sterile bare-tipped laser
fibre, 600 mm in diameter was introduced into theEur J Vasc Endovasc Surg Vol 32, December 2006catheter to its first mark (which placed its tip flush
with the end of the catheter). The catheter was then
withdrawn to the second mark on the fibre, while
keeping the position of the laser fibre fixed. This
resulted in protrusion of 2 cm of the bare-tipped laser
fibre beyond the catheter tip. The fibre was locked
in the catheter in this position. The patient was
then positioned in Trendelenburg position to aid
vein emptying.
Tumescent local anaesthetic solution was infiltrated
along the whole length of the GSV to be ablated, using
a 0.9 mm 180 mm needle under ultrasound guid-
ance. Tumescent anaesthetic solution was prepared by
diluting 30 ml of 2% lignocaine (with 1:200,000 adrena-
line), in 500 ml of saline). Tumescent local anaesthetic
was also infiltrated around branch varicosities. Total
local anaesthetic used in each case, did not exceed rec-
ommended maximum safe dose of 7 mg/kg per patient.
Laser energy was delivered endovenously using
an 810 nm diode laser generator (Diomed Ltd,
Cambridge, United Kingdom). 12 or 14 W power in
pulsed or continuous mode was utilised. During the
laser ablation process, manual compression was ap-
plied to the limb over the tip of the laser fibre to aid
vein wall apposition and improve heat conduction.
Following laser ablation of the GSV from groin to
knee, incisions of 1e2 mmweremade over varicosities,
which were then removed using toothed mosquito
artery forceps or Mu¨ller hooks. Steri-strips and gauze
dressings were applied to stab wounds.
Panelast (Lohmann & Rauscher International
GmbH & Co. KG) elastic adhesive bandage was
applied to the whole length of the treated limb post
procedure and left in place until the first follow up
at 1 week, when it was changed to a class II (30e
40 mmHg) full-length graduated support stocking
that was worn for a further 5 weeks, except during
sleep and baths. All patients were asked to walk im-
mediately after the procedure, and to return to normal
activities as soon as they felt comfortable. A 1-week
course of non-steroidal anti-inflammatory drugs was
prescribed for all patients with no contraindication
to their use.
Outcome measures
Patients were assessed for pain, GSV occlusion rates
on duplex ultrasound scan (DUS), subsequent inter-
ventions, and satisfaction.
Pain was assessed on days 1, 4 and 7 using a visual
analogue scale (VAS) rating of 0 cm (no pain) to 10 cm
(worst imaginable pain). This was entered in a diary
727New Technique for Varicose Veins Laser Therapygiven to patients at the completion of the procedure
and reviewed at 1-week follow up.
DUS was performed at 1 and 12 weeks post proce-
dure to assess SFJ and GSV occlusion. Reflux was
defined as greater than 0.5 seconds retrograde flow.
All scans were performed by the same investigator
to avoid inter observer variability.
After 6 weeks, any patient who had residual vari-
cosities was offered either injection sclerotherapy or
further ambulatory phlebectomy.
Patient satisfaction was assessed at 12 weeks using
a VAS rating of 0 cm (completely dissatisfied) to 10 cm
(completely satisfied). Patient satisfaction with cos-
metic outcome and overall treatment were assessed.
The overall treatment satisfaction was a composite
assessment that included treatment deliveries, length
of procedure, follow up treatment and recovery. It
gave an indication of patient acceptability of the
procedure.
Data from this study were found to be of non-
normal distribution and the descriptors used here
are the median and inter-quartile range (IQR).
Results
Total mean laser energy used was 83.3 Joules/cm
(range 44.5e158.4 Joules/cm). Median duration of
procedure was 69 (IQR 60e80) minutes.
Patient follow up was 100% at 1 week (n¼ 70
limbs) and 97% at 6 weeks (n¼ 68 limbs); 1 patient
was lost to follow up, while 1 patient missed appoint-
ment but attended the 12 week visit. At the time of
analysis of results, 70% (n¼ 49 limbs) had been
assessed at 12 weeks.
There were no major complications of treatment such as
skin burns, deep venous thrombosis, neuralgia or infection
of phlebectomy sites. Several patients had minor transient
bruising. 1 patient who did not take non-steroidal anti-
inflammatory drugs (NSAIDs) had thrombophlebitis at 1
week follow up. This settled with NSAID treatment. 1
patient had hyperpigmentation over the ablated GSV; this
was noticed at 6-week follow up and persisted through
the 12-week follow up.
Median pain score (Fig. 1) on day 1 was 1.6 (IQR
0.2e4.8); on day 4 was 0.3 (IQR 0e1.4) and on day 7
was 0.2 (IQR 0e1.1).
SFJ occlusion was seen in 97% (n¼ 68 of 70 limbs)
at 1 week and 96% (n¼ 47 of 70 limbs) at 12 weeks.
GSV occlusion rate was 99% (69 of 70 limbs) at 1
week, and 96% (47 of 49 limbs) at 12 weeks.
Three limbs (4%) in three patients underwent injec-
tion sclerotherapy after 6 weeks, for residual varicos-
ities. All 3 patients had thread veins. 1 patient (w1%)underwent further ambulatory phlebectomy for resid-
ual varicosities.
Median patient satisfaction with cosmetic appear-
ance was 9.6 (IQR 8.9e10) and for overall satisfaction
with treatment was 9.8 (IQR 9.3e10) (Fig. 2). 47 of the
49 patients (96%) who attended 12-week follow up said
they would have EVLTAP again.
Fig. 1. Pain scores on days 1, 4 and 7. The bar within box
represents median score; box represents interquartile range;
whiskers represent lowest and highest scores.
Fig. 2. Patient Satisfaction Rating with EVLTAP at 12 weeks.
The bar within box represents median score; box represents
interquartile range; whiskers represent lowest and highest
scores (10¼ completely satisfied).Eur J Vasc Endovasc Surg Vol 32, December 2006
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GSV laser ablation has been used in clinical practice
for about 5 years, although few studies have reported
follow-up data for this period. We have been perform-
ing EVLTcombined with ambulatory phlebectomy for
18 months. Most practitioners perform EVLT as an of-
fice procedure, with the majority of patients requiring
subsequent adjunctive therapies. This requires several
hospital visits for treatment, which may be unappeal-
ing to patients17 and may reduce cost effectiveness.18
EVLTAP does not significantly increase patient
discomfort or pain. Patients in this study reported
minimal pain, comparable to that reported by practi-
tioners of staged treatments. Unlike the experience
of Min and Khilnani,16 our patients did not complain
of delayed tightness in the lower limb following
EVLT. This may be because we routinely prescribed
non steroidal anti inflammatory medications post pro-
cedure. The absence of this delayed tightness did not
appear to herald treatment failure.
In our experience, EVLTAP took a median time of
69 minutes (IQR 60e80) to perform. This is not
unduly prolonged when compared with several series
in which EVLT has been performed alone.19,20 It is
realised that length of procedure is dependent on
length of treated vein and operator experience.
At the 3 months scan, 2 limbs (4%) demonstrated
reflux in the proximal segment of the GSV. We defined
reflux as a retrograde flow of >0.5 seconds, as recom-
mended for superficial veins.21 These 2 cases were
performed early in the series, and were associated
with total laser energy delivery below the recommen-
ded 70 J/cm for technical and clinical success.16 These
patients went on to have repeat laser ablation (not re-
included in this series). A small number of other veins
also treated with less than 70 J/cm remained occluded
at 3 months, thus suggesting that other factors may
have contributed to the early failure. SFJ occlusion/
competence was defined as flush occlusion of the
GSV at the SFJ with any patent terminal segment of
the GSV at the junction no greater than 5 mm. Although
GSV occlusion is more significant than SFJ occlusion
following EVLT, we chose to monitor SFJ occlusion
because of the possibility of developing reflux in the
tributaries around the SFJ if it is not occluded, or is in-
competent. Using this technique of flush occlusion has
not resulted in any definite case of thrombus exten-
sion into the common femoral vein (CFV) in this
series, or in the over 100 limbs done later and not in-
cluded in this present series. We have had one case of
a small eccentric thrombus in the CFV close to the SFJ,
which was not contiguous with the non-thrombotic
occlusion of the GSV. This may have been due toEur J Vasc Endovasc Surg Vol 32, December 2006migration of the tip of the laser fibre during tumescent
anaesthetic infiltration. Like Min and Khilnani,16 we
now reconfirm the position of the laser tip post tumes-
cent anaesthesia prior to firing, to ensure correct
positioning of the fibre tip.
At 6 week follow up, 3 patients had thread veins
that had become more prominent post laser ablation,
while 1 patient had several small residual varices.
None of these patients had DUS evidence of treatment
failure. The patients with thread veins underwent suc-
cessful treatment with compression sclerotherapy. The
single patient, who had residual varices, successfully
underwent further ambulatory phlebectomy. These 4
limbs accounted for fewer than 6% of the 68 limbs
seen at 6 weeks. This represents a vast reduction in
the proportion of patients needing subsequent adjunc-
tive procedures following EVLT only (30%e99%).
EVLTAP was associated with high levels of patient
satisfaction with cosmetic appearance and overall
treatment. We assessed satisfaction in 2 areas to
show that in addition to cosmetic outcome, patients
were also satisfied with the whole EVLTAP proce-
dure, and found it acceptable. Most previous studies
have assessed patients’ acceptance of EVLT in a quali-
tative way, and as in our study, they have demon-
strated an overwhelming acceptance of EVLT. The
overwhelming majority of our patients would have the
procedure again. This is an indirect evidence for acceptabil-
ity of EVLTAP.
In summary, we have found the combined proce-
dure of EVLTAP to be a feasible option, and propose
it as an alternative to present ‘‘EVLT only’’ procedure.
EVLTAP is not unduly prolonged, and not associated
with pain that limits immediate return to normal ac-
tivities. It is acceptable to patients, and vastly reduces
the number of sequential treatments required. We
would however recommend a randomised controlled
trial to compare the two treatment options.
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